We also found equivalent risk of composite CKD outcome among survivors regardless of cancer stage or ICI regimen used, which implicates the importance of long-term kidney function monitoring, especially in patients with stage 3 melanoma treated with anti-PD-1 adjuvant therapy who are expected to be long-term survivors. This evidence concerns the gene PDCD1 and cancer.